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Major depressive disorder and current psychological distress
moderate the effect of polygenic risk for obesity on body
mass index
T-K Clarke1, LS Hall1, AM Fernandez-Pujals1, DJ MacIntyre1, P Thomson2,3,4, C Hayward2,3, BH Smith5, S Padmanabhan6, LJ Hocking7,
IJ Deary4,8, DJ Porteous3,4 and AM McIntosh1,4
Major depressive disorder (MDD) and obesity are frequently co-morbid and this correlation is partly due to genetic factors.
Although speciﬁc genetic risk variants are associated with body mass index (BMI) and with larger effect sizes in depressed
individuals, the genetic overlap and interaction with depression has not been addressed using whole-genome data. Polygenic
proﬁle scores for MDD and BMI were created in 13 921 members of Generation Scotland: the Scottish Family Health Study and
tested for their association with BMI, MDD, neuroticism and scores on the General Health Questionnaire (GHQ) (current
psychological distress). The association between BMI polygenic proﬁle scores and BMI was tested ﬁtting GHQ, neuroticism or MDD
status as an interaction term to test for a moderating effect of mood disorder. BMI polygenic proﬁle scores were not associated with
lifetime MDD status or neuroticism although a signiﬁcant positive association with GHQ scores was found (P= 0.0001, β= 0.034,
r2 = 0.001). Polygenic risk for MDD was not associated with BMI. A signiﬁcant interaction between BMI polygenic proﬁle scores and
MDD (P= 0.0003, β= 0.064), GHQ (P= 0.0005, β= 0.027) and neuroticism (P= 0.003, β= 0.023) was found when BMI was the
dependent variable. The effect of BMI-increasing alleles was greater in those with MDD, high neuroticism or current psychological
distress. MDD, neuroticism and current psychological distress amplify the effect of BMI polygenic proﬁle scores on BMI. Depressed
individuals with a greater polygenic load for obesity are at greater risk of becoming obese than control individuals.
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INTRODUCTION
Major depressive disorder (MDD) is the second-leading cause of
disability worldwide.1 Part of this disability may be attributed to
physical co-morbidities that are common to MDD, such as being
overweight or obese.2 Longitudinal studies show baseline obesity
increases risk for MDD (odds ratio = 1.55, 95% conﬁdence
interval = 1.22–1.98) and that that MDD increases the odds for
developing obesity (odds ratio = 1.58; 95% conﬁdence interval =
1.33–1.87).3 One large epidemiological study found that increased
risk for obesity is conﬁned to atypical depression, a subtype of
MDD characterized by increased appetite and hypersomnia.4
Other studies have found an increased risk of past-month MDD
among obese females or individuals with severe obesity (body
mass index (BMI) ⩾ 40).5 The reciprocal relationship between
obesity and certain subtypes of MDD is not well understood. MDD
may arise as a consequence of health problems that accompany
obesity or increased appetite may be a symptom of mood
disorders.
Obesity and MDD appear to share a common genetic
architecture, that is, genetic variants that increase risk for obesity
also associate with MDD. Genetic variants in the fat-mass- and
obesity-associated FTO gene are associated with MDD. A single-
nucleotide polymorphism (SNP) in FTO (rs9939609) that explains
0.34% of the variance in obesity6 was found to confer protection
against MDD in 6561 depression cases and 21 932 controls.7
However, the rs9939609 A allele was found to increase risk for
MDD in an independent sample of 1544 cases and 2806 controls,
although after adjustment for BMI this was no longer signiﬁcant. A
signiﬁcant association was detected between rs9939609 and the
atypical subtype of MDD in this sample.8 MDD has been shown to
amplify the effect of obesity-related genetic variants on BMI. An
analysis of 88 SNPs in the FTO gene in two independent samples
comprising 3734 MDD cases and 1499 controls found consistent
evidence that MDD moderates the effect of FTO risk variants on
BMI.9
The genetic overlap between MDD and obesity/BMI is likely to
extend beyond the FTO gene. Variation in BMI has a genetic basis
with heritability estimates in the range of 40–70%.10,11 A large
genome-wide association study (GWAS) of BMI found 32 loci to be
associated at a genome-wide signiﬁcant level. These 32 loci were
found to explain 1.45% of the phenotypic variance in BMI, which is
consistent with a polygenic inheritance pattern.6 The heritability
of MDD has been estimated to be 37%12 with 21% of the variance
explained by common genetic factors, also suggesting polygenic
disease architecture.13 Twin studies in female twin pairs have
1Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK; 2Centre for Genomics and Experimental Medicine, Institute of Genetics and Molecular
Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK; 3MRC Human Genetics, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh,
Edinburgh, UK; 4Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK; 5Population Health Sciences, University of Dundee, Dundee,
UK; 6Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK; 7Division of Applied Medicine, Institute of Medical Sciences, University of Aberdeen,
Aberdeen, UK and 8Department of Psychology, University of Edinburgh, Edinburgh, UK. Correspondence: Dr T-K Clarke, Division of Psychiatry, University of Edinburgh, Royal
Edinburgh Hospital, Edinburgh EH10 5HF, UK.
E-mail: toni.clarke@ed.ac.uk
Received 4 February 2015; revised 13 May 2015; accepted 21 May 2015
Citation: Transl Psychiatry (2015) 5, e592; doi:10.1038/tp.2015.83
www.nature.com/tp
estimated that 12% of the genetic component of depression is
shared with obesity.14
The aim of this study was to assess whether BMI and MDD have
an overlapping polygenic architecture using polygenic proﬁle
scores.15 This was explored in a large population-based cohort:
Generation Scotland: the Scottish Family Health Study (GS:
SFHS).16,17 As MDD has been shown to moderate the effect of
FTO variants on BMI, we hypothesized that the association
between BMI polygenic proﬁle scores and BMI would be
moderated by the presence of MDD. We also tested whether this
extended to current psychological distress or neuroticism by using
scores on the General Health Questionnaire (GHQ-28)18 and the
Eysenck personality questionnaire for neuroticism,19 as these traits
are heritable and genetically correlated with MDD in this sample
(rG neuroticism= 0.58, rG GHQ=0.7).20 Furthermore, there is a
strong association between neuroticism and depression, and
longitudinal studies have found that high premorbid neuroticism
is a risk factor for depression.21,22
MATERIALS AND METHODS
Sample
Generation Scotland: The Scottish Family Health Study. GS:SFHS is a family-
based population cohort recruited at random from general practitioners'
practices throughout Scotland; the protocol for recruitment is described in
detail elsewhere.16,17 The full cohort consists of 23 690 individuals who
were over 18 years of age at the time of recruitment and 21 516 of these
attended the research clinic. The present study includes 13 921 individuals
for whom genome-wide genotype data were available. Demographic
information on these individuals is provided in Table 1. MDD was
diagnosed using the structured clinical interview for the Diagnostic and
Statistical Manual of Mental Disorders (SCID).23 A brief screening
questionnaire was administered to participants to screen for MDD.
Participants were asked “Have you ever seen anybody for emotional or
psychiatric problems?” and “Was there ever a time when you, or someone
else, thought you should see someone because of the way you were
feeling or acting?” If they answered yes to either of these questions (21.7%
screened positive), they were asked to complete the SCID.19 If they
answered no to both of these questions, they were assigned control status.
Answers to the SCID provided information on the presence or absence of a
lifetime history of MDD, age of onset and number of depressive episodes.
Those who completed the SCID but did not meet the criteria for MDD were
also deﬁned as controls.
Individuals with a diagnosis of bipolar disorder were removed from this
study. The GHQ (GHQ-28)18 was completed by 13 715 of the genotyped
individuals providing a measure of current psychological distress. The
GHQ-28 consists of four subscales designed to assess: (A) somatic
symptoms, (B) anxiety and insomnia, (C) social dysfunction and (D) ‘severe
depression’. The Eysenck personality questionnaire was completed by
13 838 of the genotyped individuals providing a measure of neuroticism.
BMI was calculated using height (cm) and weight (kg) measured by trained
clinical staff and was available for 13 827 individuals. All components of GS:
SFHS have received ethical approval from the NHS Tayside Committee on
Medical Research Ethics (REC Reference Number: 05/S1401/89). Written
consent for the use of data was obtained from all participants.
Genotyping and polygenic proﬁling. Blood samples were obtained using
standard operating procedures and subsequently stored at the Wellcome
Trust Clinical Research Facility Genetics Core (www.wtcrf.ed.ac.uk). Samples
were genotyped using the Illumina HumanOmniExpressExome-8v1.0
BeadChip and Inﬁnum chemistry24 and processed using the IlluminaGe-
nomeStudio Analysis software v2011.1 (Illumina, San Diego, CA, USA). The
details of blood collection and DNA extraction are provided elsewhere.17
Quality control on raw genotypes removed individuals with an overall
genotyping rate of o99%, SNPs with a minor allele frequency o1%, call
rate o99% or a signiﬁcant deviation from the Hardy–Weinberg
equilibrium (P⩾ 1× 10− 6) in founder individuals. Multidimensional scaling
components were created according to the ENIGMA 1000 genomes
protocol25 in the software package PLINK.26 Four GS:SFHS population
outliers were removed and four multidimensional scaling components
were used to correct for population stratiﬁcation in the remaining
individuals.
Polygenic proﬁle scores were created in PLINK26 according to previously
described protocols.15 Prior to creating scores, all strand-ambiguous SNPs
were removed from the GS:SFHS data set and SNPs were linkage
disequilibrium pruned using clump-based pruning (r2 = 0.25, 300 kb
window). Polygenic proﬁle scores for BMI were calculated using summary
data from a GWAS of BMI in 123 865 individuals.6 Each BMI-increasing
allele was ascribed a weight of ‘1’, as the effect sizes for the SNP–BMI
associations are not publically available. Polygenic proﬁle scores for MDD
were created using summary data from the largest available GWAS of MDD
to date comprising 9240 MDD cases and 9519 controls.27 Dudbridge
estimated that for a trait with a heritability of 44%, 1978 cases and 1978
controls in a training set would provide 80% power to detect association
with the same trait in an independent replication sample.28 As both the
MDD and BMI GWAS were substantially larger than this, we believe we
have sufﬁcient power to detect an association between polygenic proﬁle
scores and BMI/MDD in the current study. Five polygenic proﬁle scores
were created using SNPs associated with MDD or BMI with P-value
thresholds of 0.01, 0.05, 0.1, 0.5 and 1.
Statistical analysis
BMI, GHQ and neuroticism were transformed towards normality using the
Box–Cox transformation procedure implemented in the MASS package in
R.29 Continuous variables were scaled to have a mean of 0 and a s.d. of 1,
such that the reported regression coefﬁcients (beta) are standardized.
Mixed linear models implemented in the ASReml-R (www.vsni.co.uk/
software/asreml) software package were used to test the association
between polygenic proﬁle scores and BMI, GHQ, neuroticism and MDD.
Age, sex, four multidimensional scaling ancestry components and
polygenic proﬁle scores were ﬁxed effects. GS:SFHS is a family-based
study and to control for relatedness, family structure was ﬁtted as a
random effect by creating an inverse relationship matrix using pedigree
kinship information. Wald’s conditional F-test was used to calculate the
signiﬁcance of ﬁxed effects. To test the interaction of BMI polygenic proﬁle
scores with depression status/GHQ/neuroticism, an interaction term was
added to the model with BMI polygenic proﬁle scores and depression
status/GHQ/neuroticism also included as main effects. The P-values
presented are raw P-values uncorrected for multiple testing. False
discovery rate was implemented in the R package ‘fdrtools’ to estimate
the local false discovery rate. The false discovery rate threshold for
statistical signiﬁcance was estimated to be 0.009.
RESULTS
The number of individuals in the current study with a lifetime
diagnosis of MDD was 2030, and 11 836 individuals were
identiﬁed as controls. In total, 431 individuals had a diagnosis of
current depression at the time of interview. Demographic
information is provided in Table 1. MDD cases were signiﬁcantly
younger, had signiﬁcantly higher GHQ scores, were more likely to
be female, had signiﬁcantly higher neuroticism scores and had
larger BMIs than controls. Polygenic risk scores for BMI and MDD
were available for 13 921 members of GS:SFHS. The Pearson’s
correlation between the BMI and MDD polygenic proﬁle scores in
6418 randomly selected unrelated individuals at the P⩽ 0.1
Table 1. Demographic characteristics of GS:SFHS individuals in the
current study
Total
(13 921)
Lifetime MDD
(2030)
Controls
(11 836)
Age (s.d.) 48.57 (15.07) 46.89 (12.97)a 48.88 (15.38)
Sex (% female) 59% 70.7%a 54.7%
BMI (s.d.) 26.87 (5.41) 27.61 (6.18)a 26.73 (5.26)
GHQ score (s.d.) 2.41 (4.06) 5.22 (6.21)a 1.91 (3.31)
Neuroticism (s.d.) 1.32 (0.77) 1.87 (0.61)a 1.23 (0.75)
Abbreviations: BMI, body mass index; GHQ, General Health Questionnaire;
GS:SFHS, Generation Scotland: the Scottish Family Health Study; MDD,
major depressive disorder. aSigniﬁcantly different from controls at
Po2 × 10−5.
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threshold was low and non-signiﬁcant (cor = 0.002, P= 0.8).
Unrelated individuals were used for estimating correlations
between polygenic proﬁle scores to avoid confounding due to
genetic similarity between family members.
BMI polygenic proﬁle scores
BMI polygenic proﬁle scores were signiﬁcantly associated with BMI
in GS:SFHS at all P-value thresholds (Table 2). Individuals carrying
more BMI-increasing alleles had a signiﬁcantly higher BMI. The
polygenic proﬁle score, which explained most of the phenotypic
variance in BMI, was at the Po0.01 threshold (β= 0.2,
P= 1.3 × 10−118) where 4.2% of variance was explained. BMI
polygenic proﬁle scores were not signiﬁcantly associated with
MDD or neuroticism (Table 2); however, an association with GHQ
scores was observed at all P-value thresholds. Individuals scoring
higher on the GHQ were found to carry more BMI-increasing
alleles. The variance in GHQ explained by the BMI polygenic
proﬁle scores was much lower than for BMI (0.1%) ((P⩽ 0.01)
β= 0.03, P= 0.0001) (Table 2). The association between GHQ scores
and BMI polygenic proﬁle scores was reanalysed after controlling
for BMI to determine whether the association could be explained
by overweight and obese individuals experiencing more psycho-
logical distress. At the P-value threshold ⩽ 0.01, there was a ~ 33%
reduction in the effect size but a nominally signiﬁcant association
remained (β= 0.02, P= 0.019, r2 = 0.0004).
MDD polygenic proﬁle scores
MDD proﬁle scores were signiﬁcantly associated with a lifetime
history of MDD in GS:SFHS for four of the ﬁve P-value thresholds,
and the greatest amount of variance was explained using a P-
value threshold of P⩽ 0.1 (β= 0.01, P= 0.0001, r2 = 0.001)
(Supplementary Table 1). The only MDD polygenic proﬁle score
associated with BMI was the score containing SNPs associated
with MDD at a P-value threshold ⩽ 0.01 (β= 0.02, Pe = 0.011,
r2 = 0.0004), but this was not signiﬁcant after correction for
multiple testing. Robust associations between MDD polygenic
proﬁle scores and GHQ were found at each P-value threshold, and
the score explaining the greatest amount of variance was at the
P⩽ 0.05 threshold (β= 0.04, P= 9× 10−6, r2 = 0.002). At this thresh-
old, individuals carrying more MDD risk alleles had more current
psychological distress measured using the GHQ (Supplementary
Table 1). Positive associations between MDD polygenic proﬁle
scores and neuroticism were also found at each P-value threshold,
and the greatest amount of variance explained was at the P⩽ 1
threshold (β= 0.04, P= 0.0001, r2 = 0.001). Individuals who have
higher neuroticism scores carry more MDD risk alleles.
The association between polygenic risk for MDD and BMI was
tested in MDD cases only (N= 2030). No signiﬁcant associations
were found (data not shown).
Interaction between BMI polygenic proﬁle score and MDD/GHQ/
neuroticism
A signiﬁcant interaction between BMI polygenic proﬁle scores and
MDD status was found at the P-value threshold ⩽ 0.1 in relation to
BMI (β= 0.064, P= 0.0032) (Table 3). Figure 1 illustrates the
relationship between BMI polygenic proﬁle scores and BMI in
MDD cases and controls. The effect of BMI polygenic proﬁle scores
on BMI is greater in individuals with MDD (MDD cases β= 0.265 vs
controls β= 0.188). Figure 2 shows the amount of variance
explained by BMI polygenic proﬁle scores in MDD cases, controls
and the total sample. At a P-value threshold of P ⩽ 0.1, BMI
polygenic proﬁle scores explain 6.5% of the variance in BMI
among MDD cases in comparison with 3.7% of the variance in
controls. The interaction term was not signiﬁcant at the P-value
thresholds other than P ⩽ 0.1, but the direction of effect was
consistent across all ﬁve scores.
A signiﬁcant interaction between BMI polygenic proﬁle scores
and GHQ was also observed in relation to BMI, and this was
signiﬁcant for all ﬁve polygenic proﬁle scores (Table 3). The
greatest effect was seen using all SNPs (P⩽ 1) (β= 0.027,
P= 0.0005). The interaction-term effect was in the same direction
as for MDD: the effect of carrying more BMI-increasing alleles on
Table 2. Association between BMI polygenic proﬁle scores and BMI, MDD status and GHQ at ﬁve different P-value threshold cutoffs
BMI PGRS threshold BMI MDD GHQ Neuroticism
β r2 P-value β r2 P-value β r2 P-value β r2 P-value
P⩽ 0.01 0.17 0.034 1.0 ×10−93 0.001 0 0.71 0.029 0.0009 0.0009 − 0.009 0 0.29
P⩽ 0.05 0.198 0.041 7.2 ×10−117 0.002 0 0.58 0.031 0.0009 0.0004 − 0.001 0 0.91
P⩽ 0.1 0.2 0.042 1.3 ×10−118 0.004 0.0001 0.15 0.034 0.001 0.0001 0.004 0 0.66
P⩽ 0.5 0.197 0.041 7.6 ×10−115 0.003 0 0.38 0.032 0.001 0.0002 0.0005 0 0.96
P⩽ 1 0.18 0.035 2.6 ×10−100 0.002 0 0.45 0.026 0.0006 0.0027 − 0.004 0 0.66
Abbreviations: BMI, body mass index; FDR, false discovery rate; GHQ, General Health Questionnaire; MDD, major depressive disorder; MDS, multidimensional
scaling; PGRS, polygenic risk score. Covariates include age, sex and four MDS components. Bolded P-values are signiﬁcant after FDR correction.
Table 3. Interaction between BMI polygenic proﬁle scores with MDD status, neuroticism and GHQ at ﬁve different P-value threshold cutoffs
BMI PGRS
threshold
MDD× PGRS β
(s.e.)
MDD× PGRS
P-value
Cur. DEP× PGRS β
(s.e.)
Cur.
DEP× PGRS
P-value
GHQ× PGRS β
(s.e.)
GHQ× PGRS
P-value
Neurot× PGRS β
(s.e.)
Neurot× PGRS
P-value
P⩽ 0.01 0.027 (0.02) 0.21 0.090 (0.04) 0.031 0.021 (0.008) 0.009 0.014 (0.008) 0.079
P⩽ 0.05 0.041 (0.02) 0.056 0.090 (0.04) 0.040 0.022 (0.008) 0.005 0.023 (0.008) 0.004
P⩽ 0.1 0.064 (0.02) 0.0003 0.085 (0.04) 0.051 0.023 (0.008) 0.004 0.023 (0.008) 0.003
P⩽ 0.5 0.037 (0.02) 0.086 0.018 (0.05) 0.68 0.024 (0.008) 0.002 0.018 (0.008) 0.020
P⩽ 1 0.021 (0.02) 0.33 −0.003 (0.04) 0.94 0.027 (0.008) 0.0005 0.016 (0.008) 0.048
Abbreviations: BMI, body mass index; Cur.Dep, current depression; FDR, false discovery rate; GHQ, General Health Questionnaire; MDD, major depressive
disorder; PGRS, polygenic risk score. In each case the dependent variable is BMI. Bolded P-values are signiﬁcant after FDR correction.
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BMI is greater in individuals experiencing greater levels of current
psychological distress. To demonstrate this, the relationship
between BMI and BMI polygenic proﬁle score was tested in each
quartile of the GHQ score (Supplementary Figure 1). Similarly, a
signiﬁcant interaction between BMI polygenic proﬁle scores and
neuroticism scores was found when BMI was the dependent
variable. The largest effect size for the interaction was observed at
the P-value threshold of P⩽ 0.1 (β= 0.023, P= 0.003).
To test whether the effect of MDD on BMI polygenic risk was
due to current depression/mood rather than lifetime MDD status,
an interaction between current depression (N= 431) and poly-
genic risk for BMI was tested (Table 3). Nominally signiﬁcant
associations were observed at two from ﬁve P-value thresholds,
but these did not withstand correction for multiple testing.
DISCUSSION
There is little evidence for genetic overlap between BMI and MDD
in this large population-based cohort using a polygenic proﬁle
score approach. BMI polygenic proﬁle scores for BMI were not
associated with a lifetime history of MDD in GS:SFHS, and
polygenic risk for MDD was not associated with BMI. BMI
polygenic proﬁle scores and GHQ scores were positively
associated, suggesting some genetic overlap between obesity
and current psychological distress. MDD status was found to
amplify the effect of BMI polygenic proﬁle scores on BMI. BMI-
increasing alleles have a stronger effect on BMI in depressed
individuals. A similar relationship was observed with GHQ and
neuroticism. GHQ and neuroticism scores were found to moderate
the effect of BMI polygenic proﬁle scores on BMI.
Previous studies have found genetic variants in the FTO gene to
be associated with MDD.7,8 Using an aggregate score of all genetic
variants associated with BMI, we ﬁnd no association with MDD
status. The genetic overlap between MDD and BMI may be
restricted to the FTO gene, or as suggested by Milaneschi et al.,8
BMI risk variants may only be relevant for atypical depression. We
do ﬁnd modest genetic overlap between BMI and GHQ scores, as
individuals with higher GHQ scores were found to carry more
Figure 1. Relationship between BMI polygenic proﬁle scores and measured BMI in Generation Scotland: the Scottish Family Health Study. Bars
represent the total sample, cases or controls at each polygenic proﬁle score P-value threshold cutoff. The y axis represents the standardized
beta for the association between BMI polygenic proﬁle score and BMI, error bars represent s.e. BMI, body mass index; GS:SFHS, Generation
Scotland: the Scottish Family Health Study; MDD, major depressive disorder; PGRS, polygenic risk score.
Figure 2. Proportion of variance in BMI explained by BMI polygenic proﬁle scores at ﬁve different thresholds in GS:SFHS (14 k). DEP= 2030
MDD cases, CONS= 11 836 controls, TOTAL= 13 921 of total sample. All associations signiﬁcant at P⩽ 3.2 × 10− 19. BMI, body mass index;
DEP, major depressive disorder; GS:SFHS, Generation Scotland: the Scottish Family Health Study; PGRS, polygenic risk score.
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BMI-increasing alleles. One explanation for this is that BMI-
increasing genetic variants increase risk for current psychological
distress but not lifetime MDD. Alternatively, there may be genetic
overlap between BMI and MDD, but we have greater power to
detect an association with GHQ scores due to the trait being
continuous versus binary. High GHQ scores have previously been
found to be associated with obesity,30,31 and it has been
suggested that obesity increases the risk for common mental
disorders as indexed by the GHQ.32 We also ﬁnd no association
between BMI polygenic proﬁle scores and neuroticism, further
suggesting that it is current psychological distress (measured
using the GHQ) rather than a tendency to lower mood that
overlaps with polygenic risk for BMI.
A recent study of SNPs across the FTO gene found that
depressive status moderated the association with BMI in 10 of the
SNPs studied. They found a signiﬁcant association between FTO
variants and BMI in depression cases, but not controls in two
independent samples.9 In support of this, we ﬁnd that BMI
polygenic proﬁle scores are more strongly associated with and
explain more of the variance in BMI in depressed individuals
compared with controls. This was also found in relation to GHQ
and neuroticism. GHQ and neuroticism moderated the effect of
BMI polygenic proﬁle scores on BMI. Therefore, the effect of
depression status on BMI-increasing alleles is not restricted to the
FTO gene, but is observed across the spectrum of polygenic
variation associated with BMI.
Psychological distress and depression are associated with
disordered eating.33 In individuals at high genetic risk for obesity,
the presence of mood disorders may have a greater impact on
weight gain than those at low genetic risk. Cortisol levels are often
increased in depressed individuals or those who have experienced
stress. Elevated cortisol increases insulin secretion, which in turn
promotes the accumulation of abdominal fat.34 Longitudinal
studies have shown that baseline depression is associated with
increased abdominal and visceral fat 5 years later.35 A recent study
of 58 healthy women assessed for depression and previous-day
stress were given two high-fat meals and found those who
experienced the most stressors had the lowest postprandial
resting energy expenditure.36 We ﬁnd that in individuals with
MDD or high GHQ scores, the effect of BMI-increasing alleles on
BMI is increased. Further work is needed to understand the
biological mechanisms that cause mood to inﬂuence BMI.
However, these data suggest that increased BMI may be a
response to endocrine ﬂuctuations stimulated by current mood or
lifetime depression, which then interacts with a genetic propensity
to obesity.
There are a number of limitations to this study. The number of
individuals in the reference MDD GWAS, which was used to create
the polygenic risk scores, was low compared with the BMI GWAS
(18 759 vs 123 865 total sample: 0 GWAS signiﬁcant hits vs 19
GWAS signiﬁcant hits). The power to detect association between
the two disorders is biased towards the BMI polygenic proﬁle
scores. BMI polygenic proﬁle scores are able to explain 4% of the
variance in BMI, whereas MDD polygenic proﬁle scores explain
only 0.1% of the variance in MDD. We may have detected genetic
overlap between BMI and MDD if the original GWAS for MDD were
larger. Despite seeing a greater effect of BMI polygenic proﬁle
scores among depressed individuals, the amount of variance they
explain is low, only 6.5% in this population. Another limitation is
that previous studies have shown that the effect of BMI-increasing
risk alleles is differential across MDD subtypes,8 and that atypical
depression has a greater overlap with BMI. Atypical depression is
characterized by hypersomnia and increased appetite and these
cases typically present with a higher BMI than controls. In the
present study, we did not restrict our analyses to obese or atypical
cases as we chose to maximise our power to detect association in
the available sample. Future studies including larger case–control
samples would beneﬁt from considering atypical depression
status, although we note that the evidence suggesting that this
is a valid and clinically useful stratiﬁcation of depression is
inconclusive.
Depression accounts for 8.2% of years lost to disability
worldwide each year.1 Much of this disability is due to co-
morbid physical conditions, which are partially explained by
increased rates of overweight and obesity.2 We ﬁnd that among
individuals displaying current psychological distress or who have a
lifetime diagnosis of MDD, BMI-increasing alleles have a stronger
effect on BMI. Future studies replicating this ﬁnding are needed to
conﬁrm their signiﬁcance, although this is the second study to
show that MDD ampliﬁes the effect of BMI-related genetic
variants. By understanding the relationship between MDD and
obesity we can better understand their mechanisms and develop
interventions to reduce their considerable burden on those
affected.
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